TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InhaleRx Limited ( (AU:IRX) ) has provided an announcement.
InhaleRx Limited has announced the addition of SRX-25, a ketamine-based oral fixed-dose drug, to its development pipeline, targeting treatment-resistant depression (TRD). This new formulation aims to improve patient access and adherence by offering a more convenient oral administration compared to existing intranasal options. The development will utilize the 505(b)(2) regulatory pathway to expedite progress and reduce costs, with funding support from the Linlithgow Family Office. The global TRD market is expected to grow significantly, and SRX-25 could enhance InhaleRx’s market position by addressing current treatment limitations and expanding patient reach.
More about InhaleRx Limited
InhaleRx Limited operates in the pharmaceutical industry, focusing on the development of innovative drug therapies. The company specializes in creating treatments for mental health conditions, with a particular emphasis on addressing unmet needs in treatment-resistant depression (TRD).
Average Trading Volume: 257,297
Technical Sentiment Signal: Hold
Current Market Cap: A$7.85M
See more insights into IRX stock on TipRanks’ Stock Analysis page.